Nothing Special   »   [go: up one dir, main page]

MX2021002967A - Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3. - Google Patents

Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3.

Info

Publication number
MX2021002967A
MX2021002967A MX2021002967A MX2021002967A MX2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A
Authority
MX
Mexico
Prior art keywords
methods
disease
ccr3
inhibitors
compositions
Prior art date
Application number
MX2021002967A
Other languages
English (en)
Inventor
S Sakura Minami
Karoly Nikolich
Braithwaite Steven P
Sanket V Rege
Arnaud E J Teichert
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of MX2021002967A publication Critical patent/MX2021002967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a método para mejorar enfermedades neurodegenerativas con agentes moduladores de CCR3; los métodos incluyen administrar una cantidad terapéuticamente efectiva del agente modulador de CCR3 al sujeto, con una mejora concomitante en la función cognitiva, motora u otra función afectada de manera neurodegenerativa; las enfermedades cognitivas y motoras en las que los métodos de la invención pueden mejorar la cognición incluyen la enfermedad de Alzheimer, enfermedad de Parkinson, demencia frontotemporal, enfermedad de Huntington, esclerosis lateral amiotrófica, esclerosis múltiple, glaucoma, distrofia miotónica, demencia vascular, parálisis supranuclear progresiva.
MX2021002967A 2018-09-26 2019-09-25 Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3. MX2021002967A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
PCT/US2019/052995 WO2020069008A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Publications (1)

Publication Number Publication Date
MX2021002967A true MX2021002967A (es) 2021-08-11

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002967A MX2021002967A (es) 2018-09-26 2019-09-25 Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3.

Country Status (16)

Country Link
EP (1) EP3856195A4 (es)
JP (2) JP7528065B2 (es)
KR (1) KR20210065950A (es)
CN (1) CN112789044A (es)
AU (1) AU2019346456A1 (es)
BR (1) BR112021004938A2 (es)
CA (1) CA3111433A1 (es)
CL (1) CL2021000724A1 (es)
CO (1) CO2021003713A2 (es)
EA (1) EA202190463A1 (es)
IL (1) IL281578A (es)
MA (1) MA53743A (es)
MX (1) MX2021002967A (es)
SG (1) SG11202102105VA (es)
TW (1) TW202027752A (es)
WO (1) WO2020069008A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
BRPI1014669A2 (pt) * 2009-04-22 2017-07-18 Axikin Pharmaceuticals Inc antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
JP2020513005A (ja) * 2017-04-05 2020-04-30 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
US11590118B2 (en) * 2017-04-05 2023-02-28 Alkahest Inc. Methods and compositions for treating retina-associated disease using CCR3-inhibitors

Also Published As

Publication number Publication date
JP7528065B2 (ja) 2024-08-05
BR112021004938A2 (pt) 2021-06-01
SG11202102105VA (en) 2021-04-29
WO2020069008A1 (en) 2020-04-02
EP3856195A4 (en) 2022-06-22
EA202190463A1 (ru) 2021-06-29
IL281578A (en) 2021-05-31
MA53743A (fr) 2022-01-05
EP3856195A1 (en) 2021-08-04
AU2019346456A1 (en) 2021-04-15
CL2021000724A1 (es) 2021-10-15
JP2022502441A (ja) 2022-01-11
CA3111433A1 (en) 2020-04-02
KR20210065950A (ko) 2021-06-04
CN112789044A (zh) 2021-05-11
JP2024153742A (ja) 2024-10-29
CO2021003713A2 (es) 2021-04-08
TW202027752A (zh) 2020-08-01

Similar Documents

Publication Publication Date Title
MX2019011988A (es) Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3.
WO2018015573A3 (en) Trem2 cleavage modulators and uses thereof
PH12018502028A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
PH12019500004A1 (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
EA201991756A1 (ru) Бисгетероарильные производные в качестве модуляторов агрегации белков
EA201991755A1 (ru) Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
EA201991375A1 (ru) Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
MX2021001456A (es) 2-arilbenzimidazoles como activadores de ppargc1a para tratar enfermedades neurodegenerativas.
BR112021002090A8 (pt) Derivado azabicíclico opticamente ativo
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
MX2017011598A (es) Metodos para tratar proteinopatias.
PH12021552217A1 (en) Macrocyclic azolopyridine derivatives as eed and prc2 modulators
PH12020551779A1 (en) Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
WO2018013775A3 (en) Granulin compositions and uses related thereto
IL309208A (en) Neuroactive steroids for the treatment of Alzheimer's disease
WO2020117031A3 (en) Composition and method for inhibiting amyloid beta accumulation and/or aggregation
MX2021002967A (es) Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3.
JP2017519798A5 (es)
EA201991753A1 (ru) Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков
TW200635589A (en) Therapeutic agents
WO2020092102A3 (en) 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of the m4 muscarinic acetylcholine receptor
EA201992188A1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
MX2022007654A (es) Compuestos inhibidores de la oga.
MA54630B1 (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives